Novo Nordisk stock pre-market drops 11%, Eli Lilly pre-market rises over 4%, Novo Nordisk’s CagriSema underperforms Eli Lilly’s Zepbound in trials.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Novo Nordisk drops 11% pre-market on US stocks, Eli Lilly rises over 4% pre-market
Novo Nordisk stock pre-market drops 11%, Eli Lilly pre-market rises over 4%, Novo Nordisk’s CagriSema underperforms Eli Lilly’s Zepbound in trials.